Novo Nordisk (NVO, Financial) shares climbed more than 6% on Wednesday pre-market trading after the company reported solid first-quarter results, driven by robust demand for its diabetes and obesity treatments

First-quarter revenue rose 19% year-over-year, bolstered by a 21% increase in sales of diabetes and obesity care products. Wegovy, a key GLP-1 therapy, posted an 83% surge in global sales, while U.S. revenue grew 20% as the company anticipated improved supply in the second half of 2025, with compounded GLP-1 drugs being phased out.

However, despite strong growth, Wegovy sales missed expectations, prompting the company to lower its full-year 2025 guidance. Novo Nordisk now expects sales to increase 13% to 21% for the year, down from a prior forecast of 18% to 26%. It also cut its operating profit growth forecast to 16% to 24% at constant exchange rates, down from an earlier estimate of 19% to 27%, citing slower-than-expected uptake of branded GLP-1 drugs in the U.S.

The company also noted that currency effects could reduce reported growth by 3 to 5 percentage points, reflecting ongoing exchange rate volatility.

Is Nova Nordisk a Buy After Earnings?

Based on the one year price targets offered by 9 analysts, the average target price for Novo Nordisk AS is $95.44 with a high estimate of $127.32 and a low estimate of $63.96. The average target implies a upside of +43.97% from the current price of $66.29.

Based on GuruFocus estimates, the GF Value for Novo Nordisk in one year is projected to be $158.09, implying a substantial upside of 138.48% from the current price of $66.29.